B.E. Reardon

Papers

1

Total Citations

2

H-Index

1

About

B.E. Reardon is a leading oncologist and surgeon whose work focuses on the de-intensification of treatment for HPV-related oropharyngeal cancers. Their research is centered on reducing the long-term toxicity of cancer therapies while maintaining excellent oncologic outcomes, particularly through the integration of transoral robotic surgery (TORS). Reardon’s most notable contribution is the Phase II study on volume and dose de-intensification following TORS and neck dissection for p16+ oropharyngeal squamous cell carcinoma, a landmark investigation that has already garnered 2 citations. This work demonstrates how precise surgical staging can allow for lower radiation doses, sparing patients from severe swallowing difficulties and other side effects. Reardon’s research is pivotal in shifting the paradigm from aggressive, one-size-fits-all treatment to a more tailored, risk-adapted approach. Their achievements highlight a commitment to improving quality of life for survivors of head and neck cancer, making them a key figure in the movement toward personalized, less morbid therapies.

Research Focus

Key Achievements

1
H-Index
1
Papers
2
Total Citations
2
Avg Citations/Paper
🏆 Most Cited Paper
A Phase II Study of Volume and Dose De-Intensification Following Transoral Robotic Surgery (TORS) and Neck Dissection for p16+ Oropharyngeal Squamous Cell Carcinoma
2 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 16

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago